Protagonist Therapeutics Inc.

Dr. Samuel R. Saks, MD, is a Chief Medical Officer at Protagonist Therapeutics, Inc. He is on the Board of Directors at NuMedii, Inc., Bullet Biotechnology, Inc., Velocity Pharmaceutical Development LLC and Quanta Therapeutics, Inc. Dr. Saks was previously employed as an Independent Director by PDL BioPharma, Inc., an Independent Director by Tonix Pharmaceuticals Holding Corp., a Chief Medical Officer by Threshold Pharmaceuticals, Inc., a Director & Chief Development Officer by Auspex Pharmaceuticals, Inc., a Chief Executive Officer by Jazz Pharmaceuticals, Inc., a Group Chairman by ALZA Corp., a Professor by University of California, a Group Vice President by ALZA Pharmaceuticals, a Principal by Genentech, Inc., an Advisor by CMEA Capital, an Advisor by ProQuest Investments, a Principal by Schering-Plough Corp., and a Vice President-Clinical Research by XOMA Corp. He also served on the board at Depomed, Inc., Cougar Biotechnology, Inc. /Old/, Trubion Pharmaceuticals, Inc., Corixa Corp., Coulter Pharmaceuticals, Inc., Hinge Bio, Inc., Ilypsa, Inc., Qwell Pharmaceuticals, Inc. and Sirna Therapeutics, Inc. He received his undergraduate degree from the University of Illinois and a doctorate degree from the University of Illinois.